Related by context. All words. (Click for frequent words.) 83 randomized controlled 81 multicenter 80 randomized clinical 79 prospective randomized controlled 79 multicenter randomized 78 randomized placebo controlled 77 randomized multicenter 76 blind randomized 76 placebo controlled 76 blind randomized placebo 76 randomized double 75 randomized 75 multicentre 75 prospective multicenter 74 placebo controlled randomized 74 randomized controlled clinical 73 multicenter prospective 73 Phase III randomized 73 multicentre randomized 73 nonrandomized 73 randomized Phase III 71 multicenter randomized double 71 randomized controlled trial 71 double blind placebo 71 multicenter randomized placebo controlled 70 multicenter clinical 70 multicenter study 70 multicentre randomized double 69 label multicenter 69 multicenter randomized controlled 69 double blinded randomized 69 masked placebo controlled 68 prospective multicenter randomized 68 placebo controlled clinical 68 prospective randomized multicenter 68 controlled multicenter 68 randomized trials 67 prospective randomized placebo 67 randomized clinical trials 67 prospective observational 66 blind multicenter 66 Randomized 66 blind placebo controlled 66 blind randomized controlled 66 double blinded placebo 66 active comparator 66 randomized blinded 65 multicenter multinational 65 Multicenter 65 multicenter placebo controlled 65 placebo controlled Phase 65 Phase IIIb 65 dose escalation trial 65 multicentre study 65 multicenter randomized clinical 65 randomized multicentre 64 phase IIIb 64 REALITY Trial 64 label dose escalation 64 multicenter Phase II 64 TMC# C# 64 randomized Phase IIb 64 RE LY ® 64 blinded placebo controlled 64 prospective nonrandomized 64 Phase 2b study 64 placebo controlled studies 64 randomized multicenter trial 63 dose escalation study 63 randomized controlled clinical trials 63 randomized controlled trials 63 TAXUS ATLAS 63 dose escalation Phase 63 placebo controlled Phase III 63 phase IIb clinical 63 blinded randomized controlled 62 Phase 1b clinical 62 subanalysis 62 randomized #:# 62 RE LY 62 trials RCTs 62 phase IIa clinical 62 EVEREST II 62 PRECISE 62 blinded randomized 62 Stenting Trial CREST 62 Phase IIb trial 61 phase IIb 61 label dose titration 61 placebo controlled trials 61 blind placebo 61 dabigatran etexilate 61 Randomised 61 SPIRIT III 61 Randomized Evaluation 61 dose escalation 61 multicenter Phase III 61 dose dose escalation 61 landmark ATHENA 61 clinical trial 61 ExTRACT TIMI 61 Carotid Revascularization Endarterectomy vs. 61 randomized Phase 61 sirolimus eluting stent 61 Phase 2a clinical 61 Phase IIb 61 EchoCRT 61 BRIM2 61 multicentre randomized controlled 61 PFO closure 61 subgroup analyzes 61 comparing XIENCE V 60 non inferiority 60 prospective cohort 60 multicentre prospective 60 ONTARGET 60 everolimus eluting stent 60 PREVAIL 60 sirolimus eluting 60 prospectively randomized 60 PFO migraine 60 multicenter Phase 60 NO# [002] 60 noninferiority 60 substudy 60 Phase 2b clinical 60 multinational multicenter randomized 60 Randomized controlled 60 Sorafenib HCC Assessment 60 EURIDIS 60 label multicenter Phase 60 nab paclitaxel 59 observational study 59 Phase IIIb clinical 59 SPIRIT FIRST 59 carotid stenting 59 phase IIa 59 prospective multicentre 59 paclitaxel eluting stents 59 blind multicentre 59 TG MV 59 Phase 2a trial 59 analgesic efficacy 59 MIST II 59 Phase 2b randomized 59 randomized crossover 59 Phase 2b trial 59 multicenter phase 59 placebo controlled dose escalation 59 viral kinetic 59 AIR CF3 59 Placebo controlled 59 ROCKET AF 59 randomized blinded placebo 59 DAPT 59 eptifibatide 59 SPIRIT IV 59 ENDEAVOR IV 59 randomized controlled Phase 59 Val HeFT 59 Phase III pivotal 58 NATRECOR ® 58 Phase IIIb study 58 TAXUS V 58 sirolimus eluting stents 58 multicenter trials 58 Phase III clinical 58 everolimus eluting stents 58 STENT 58 neoadjuvant 58 Prospective Randomized 58 retrospective observational study 58 label multicenter randomized 58 retrospective cohort study 58 rosuvastatin 58 Phase 2b 58 ascending dose 58 BARI 2D 58 pivotal Phase III 58 confirmatory Phase III 58 MADIT II 58 oral rivaroxaban 58 eluting stent 58 COMFORT II 58 CUSTOM II 58 ECASS 58 PRECiSE 58 ADVANCE PD 58 NSTE ACS 58 Phase IIa 58 patients undergoing percutaneous 58 Edge STudy 58 ASTEROID 58 GEM OS1 58 phase Ib 58 Phase IIa trial 58 TRITON TIMI 58 Prospective Randomized Trial 58 elective PCI 58 carotid artery stenting 58 randomized controlled multicenter 58 Phase Ib clinical 58 pivotal Phase 58 ABSORB trial 58 PRoFESS 57 CYPHER ® Stent 57 Pivotal Trial 57 Randomized Clinical Trial 57 ASCEND HF 57 confirmatory clinical 57 Phase 1b 57 pharmacokinetic PK 57 HCV SPRINT 57 e HEALING 57 CYPHER R Stent 57 pegylated interferon alfa 2b 57 prospective multicenter study 57 CALGB 57 carotid endarterectomy CEA 57 blind randomized multicenter 57 Phase Ib 57 recurrent malignant glioma 57 NICE SUGAR 57 PRE SURGE 57 Phase #/#a 57 chemoradiotherapy 57 controlled multicenter Phase 57 meta analysis 57 Phase 1b trial 57 Augment Injectable 57 VADT 57 ATTRACT 57 EDEMA3 57 coronary intervention 57 Phase 2b kidney transplant 57 paclitaxel eluting stent 57 SYNTAX 57 Thrombolysis 57 metastatic HRPC 57 CARE HF 57 unblinding 57 Phase IIb clinical 57 Myocardial Infarction Study 57 APPRAISE 57 fallopian tube cancers 57 CYPHER ® Sirolimus eluting 57 Clinical Antipsychotic Trials 57 LUX Lung 56 tolerability 56 dose regimens 56 CYPHER R Sirolimus eluting 56 observer blinded randomized 56 TAXUS IV 56 TAXUS stent 56 Endovascular Valve Edge 56 SYNTAX trial 56 telmisartan 56 recurrent GBM 56 bosentan 56 NEVO 56 RIO Lipids 56 AIR CF1 56 ticagrelor 56 Patency 56 dose titration 56 patients undergoing CABG 56 Phase III multicenter 56 ocular hypertension 56 unblinded 56 TAXUS Liberte Stent 56 Taxus Stent 56 pharmacokinetics PK 56 liver resection 56 NSABP B 56 ENESTnd 56 NCT# ClinicalTrials.gov 56 adalimumab 56 blinded randomized placebo controlled 56 Tryton Side Branch 56 sequential dose escalation 56 XIENCE V demonstrated 56 HORIZONS AMI trial 56 noninferior 56 CLARITY study 56 unfractionated heparin UFH 56 post hoc 56 tirofiban 56 AIR2 Trial 56 Acute Myocardial Infarction 56 AIM HIGH 56 Acute Ischemic Stroke 55 oral deforolimus 55 Genous stent 55 CA4P 55 liver transplant recipients 55 intravitreal injection 55 RESOLUTE 55 Phase III 55 longitudinal cohort study 55 rALLy clinical trial 55 Intervention Effectiveness 55 BRIM3 55 evaluating REVLIMID 55 CORD II 55 angiotensin receptor blocker ARB 55 AVERROES 55 BOLDER II 55 HCV RESPOND 2 55 ABCSG 55 dose escalation clinical 55 Betaferon ® 55 carotid artery stenting CAS 55 Augment Injectable Bone Graft 55 rt PA 55 AIR CF2 55 phase 2a 55 randomized placebo 55 Zilver PTX 55 Phase 2a 55 ACCOMPLISH 55 prospectively defined 55 ATACAND 55 Phase Ib II 55 OPCAB 55 NEVO RES 55 ENDEAVOR 55 severe aortic stenosis 55 safety tolerability pharmacokinetics 55 phase IIb study 55 Phase III randomized controlled 55 Platelet Inhibition 55 rFVIIa 55 OLYMPIA registry 55 single ascending dose 55 fosbretabulin 55 CYPHER Stent 55 riociguat 55 hypertensive patients 55 thrombus aspiration 55 TRANSFORMS 55 Phase IIa clinical 55 colesevelam HCl 55 Stenting 55 MEND CABG 55 pharmacodynamics PD 55 PERSEUS 55 PICSO ® 55 Phase IIB 55 GOUT 55 Phase III metastatic melanoma 55 RE LY trial 55 GORE VIABAHN Endoprosthesis 55 ACCLAIM 55 Sirolimus eluting 55 DAPT Study 54 teriflunomide 54 carotid artery stent 54 Microplasmin 54 Phase 1a 54 thromboembolic events 54 Protelos 54 ACUITY trial 54 Coronary Stent 54 PROMUS Element Stent 54 LEXIVA r 54 observational studies 54 registrational Phase 54 ascending dose study 54 Heart Failure Trial 54 sunitinib malate 54 phase III ACCLAIM 54 stage IIIB 54 Phase III VISTA 54 randomized #:#:# 54 non valvular atrial 54 icatibant 54 Efficacy 54 Radiation Therapy Oncology 54 bolus dose 54 treatment naive genotype 54 IMPROVE HF 54 II Clinical Trial 54 mg BID 54 VITAL Trial 54 acute PAO 54 Randomized Double Blind Placebo 54 RCTs 54 MERLIN TIMI 54 REALIZE 54 APTIVUS 54 evaluable patients 54 #mg/day [001] 54 safety tolerability 54 randomized Phase 2b 54 transcatheter aortic valve implantation 54 TAXUS Liberte Long 54 placebo controlled clinical trials 54 Drug Eluting Stents 54 acute ischemic stroke 54 Stent System 54 Sirolimus eluting Coronary Stent 54 meta analyzes 54 XIENCE V PROMUS Stent 54 peginterferon alfa 2b 54 coronary interventions 54 MADIT CRT 54 ARIXTRA 54 APEX PD 54 Phase III placebo controlled 54 darunavir ritonavir 54 TAXUS 54 RSD# oral 54 sunitinib 54 evaluating tivozanib 54 DU #b 54 dosing regimens 54 ZYBRESTAT fosbretabulin 54 bronchial thermoplasty 54 sorafenib Nexavar 54 STICH trial 54 HeFT 54 fondaparinux 54 abciximab 54 dosage regimens 54 LITHE 54 tiotropium 54 dosing cohorts 54 composite endpoint 54 percutaneous intervention 54 dual antiplatelet therapy 54 Infarct 54 TAXUS VI 54 retrospective cohort 54 antihypertensive therapy 54 safety tolerability pharmacokinetic 54 Edwards SAPIEN valve 54 bivalirudin 54 Percutaneous Coronary Intervention 54 Multicenter Randomized Double 54 EORTC 54 phase IIb trial 54 IFN alfa 54 Left Ventricular Dysfunction 54 monotherapy 54 TAXUS Express2 54 statin therapy 54 placebo controlled multicenter 54 multicentric 54 TAXUS TM 54 Phase III randomized placebo 54 Restenosis 53 BOLDER 53 CIMZIA TM certolizumab pegol 53 Aggressive Drug Evaluation 53 Multicentre 53 XIENCE V Everolimus Eluting 53 BoNTA 53 observational cohort study 53 LCP AtorFen 53 Randomized Phase 53 ABSORB clinical 53 subtrochanteric 53 cilostazol 53 pioglitazone 53 vertebroplasty 53 DSMB 53 candesartan cilexetil 53 AVOREN 53 RRMS patients 53 STEMI patients 53 ACTEMRA TM 53 pharmacodynamic profile 53 STRIDE PD 53 CYPHER R stent 53 comparator arm 53 CUSTOM III 53 #:# randomization 53 landmark ATHENA trial 53 radical cystectomy 53 REVLIMID lenalidomide 53 hemodialysis patients 53 BR.# 53 European Sepsis Trial 53 ILLUMINATE 53 TAXUS Liberte stent 53 Prospective Multicenter 53 irbesartan 53 relapsed myeloma 53 CHAMPION PCI 53 IABP 53 CELLO 53 Abciximab 53 recurrent glioblastoma multiforme 53 mg administered orally 53 pharmacodynamics 53 endarterectomy 53 Placebo Controlled 53 transfemoral 53 Eluting Stent 53 phakic 53 Endarterectomy 53 mycophenolate mofetil 53 viral kinetics 53 aliskiren 53 NATRECOR R 53 efficacy 53 anti arrhythmic drug 53 UPLIFT 53 pain palliation 53 International Verapamil SR 53 ischemic cardiomyopathy 53 warfarin therapy 53 Eluting Coronary Stent System 53 Coronary Stent System 53 PREVENT IV 53 SWOG 53 stenting 53 brivaracetam 53 NEVO ™ 53 Randomized Placebo Controlled 53 carboplatin paclitaxel 53 IMPACT DCM 53 ToGA 53 paclitaxel eluting 53 stent restenosis 53 ANCHOR trial 53 Val MARC 53 oral ridaforolimus 53 ENDEAVOR II 53 graft patency 53 L PPDS 53 factorial design 53 carotid stents 53 SUPERA stent 53 Angiographic 53 Phase III Clinical Trial 53 dose placebo controlled 53 beta blocker therapy 53 randomized multicenter Phase III 53 PREZISTA r 53 lacosamide 53 primary endpoint 53 prospective observational cohort 53 symptomatic BPH 53 MIVI III 53 daily Infergen 53 ongoing Phase 1b 53 Diabetic Macular Edema 53 SABCS 53 SUCCEED trial 53 Phase Ia 53 thorough QT 53 Phase IIb III 53 TAXUS Liberte 53 ThermoDox ® 53 NCCTG 53 Group RTOG 53 OMS# 53 mg QD 53 RTOG 53 RG# ITMN 53 bevacizumab 53 #mg QD [002] 53 ADMIRE HF 53 GP IIb IIIa inhibitor 53 Stenting Trial 53 ENGAGE AF TIMI 53 CLL8 53 Phase IIb randomized 53 phase III SIMPADICO 53 BCIRG 53 Traficet EN 53 tolvaptan 53 dose escalation phase 53 mg dose 53 Dacogen injection 53 Amrubicin 53 glycoprotein IIb IIIa inhibitor 53 Phase Ib study 53 Randomized Study 53 Controlled Trial 53 Clinical Outcomes Utilizing Revascularization 53 clinical pharmacology studies 52 cetrorelix 52 RE SURGE 52 neoadjuvant treatment 52 tapentadol ER 52 pimecrolimus cream 52 TACE 52 RE MODEL 52 plus ribavirin 52 HORIZONS AMI 52 SIMPADICO 52 EVIZON 52 TAXUS Stent 52 pharmacodynamic effects 52 efficacy tolerability 52 Prostate Lung Colorectal 52 Adlea 52 Feasibility Trial 52 ALLHAT 52 transurethral resection 52 CHARISMA trial 52 IMPROVE IT 52 RIBBON 52 CABANA 52 teriparatide 52 cinacalcet 52 Heparin Bioactive Surface 52 morphometric vertebral fractures 52 doxorubicin docetaxel 52 Randomized Phase II 52 CALGB # [002] 52 eplerenone 52 Ranolazine 52 undergoing elective percutaneous 52 XIENCE V Stent System 52 antithrombotic therapy 52 pharmacokinetic PK study 52 FASLODEX 52 MitraClip 52 EFAPROXYN 52 PRIMO CABG 52 HeartNet 52 TMC# r 52 Scandinavian Simvastatin Survival 52 Coronary Artery Bypass Graft 52 Phase 1a clinical 52 RECORD1 52 Initiated Phase 52 edoxaban 52 ThermoDox 52 Multaq R 52 ACTIVE W 52 stent implantation 52 unstable angina UA 52 ritonavir boosted 52 Chronic Heart Failure 52 NOXAFIL Oral Suspension 52 antiplatelet drugs 52 EmbraceAC 52 VICTOR E1 52 vitreous hemorrhage 52 TELCYTA 52 EINSTEIN DVT 52 tocilizumab 52 prospective longitudinal 52 landmark ATHENA study 52 RADIANT 52 Doxil ® 52 Endeavor Resolute 52 HPTN 52 unfractionated heparin 52 MEND CABG II 52 NCT# 52 Randomized Controlled Trial 52 transapical 52 CRESTOR #mg 52 lymphadenectomy 52 Aggressive Reduction 52 CRVO 52 antiplatelet therapy 52 Endeavor drug eluting 52 induced macular edema 52 multicenter clinical trials 52 Cardiac Allograft Rejection 52 STARFlex R 52 Randomized Double blind 52 acute coronary syndromes ACS 52 ruboxistaurin 52 FOLFOX 52 GAMMAGARD 52 platelet inhibitor 52 adjunctive placebo 52 Intervention Effectiveness CATIE 52 eculizumab 52 multiple ascending dose 52 NEVO TM 52 strontium ranelate 52 thromboembolic 52 Pharmacokinetic 52 Trandolapril 52 thromboprophylaxis 52 ABSORB 52 ACTEMRA 52 LPV r 52 Long Lesion 52 ARCOXIA 52 vicriviroc 52 Phase Ib clinical trials 52 treatment naïve genotype 52 Randomized Comparison 52 PROMACTA 52 rivaroxaban 52 Polyp Prevention Trial 52 TIMI 52 retinal vein occlusion induced 52 FOLPI 52 olmesartan 52 TAXUS Express Stent 52 deferiprone 52 thrombolytic therapy 52 XIENCE V stent 52 nonoperative 52 symptomatic VTE 52 confirmatory Phase 52 GEM OS2 52 WallFlex Biliary RX 52 Rheos System 52 pertuzumab 52 PERSEUS clinical program 52 CURRENT OASIS 7 52 registrational trial 52 PreCISe 52 Raloxifene Evaluation MORE 52 randomization 52 insulin detemir 51 plus prednisone 51 Rosuvastatin 51 saphenous vein grafts 51 nephron sparing surgery 51 Intervention Trial 51 blinded placebo 51 plus dexamethasone 51 esomeprazole 51 primary patency 51 Dabigatran 51 zonisamide SR 51 OZURDEX ® 51 zalutumumab 51 ACRIN 51 macrovascular 51 nesiritide 51 ALLEGRO 51 Monotherapy 51 FOSRENOL R 51 AEGR 51 GetGoal Phase III 51 CABERNET 51 intra articular injection 51 Phase #b/#a 51 Myocardial Infarction 51 PROMUS 51 OZURDEX 51 AZILECT R 51 tolerability pharmacokinetics 51 ThermoDox R 51 renal tumors 51 efficacy endpoint 51 Combo Stent 51 relapsed refractory multiple myeloma 51 percutaneous coronary intervention 51 phase Ib clinical 51 antiplatelet agent 51 eprotirome 51 cortical stimulation 51 oral Xeloda 51 valvulopathy 51 dose cohorts 51 Phase 1b dose escalation 51 oral diclofenac 51 candesartan 51 Carotid 51 efficacy endpoints 51 controlled dose escalation 51 noninfectious uveitis 51 RoACTEMRA 51 total hip arthroplasties 51 lipid lowering therapy 51 Phase III Trial 51 DCCT 51 Intravitreal 51 Rasilez Tekturna 51 virologic 51 Cholesterol Levels SPARCL 51 assessing T DM1 51 Acute Coronary Syndromes ACS 51 cisplatin vinorelbine 51 n = 51 bolus injection 51 MIRAPEX 51 NeuroFlo 51 azacitidine 51 MIRCERA 51 IN.PACT 51 REVIVE Diabetes 51 fluvastatin 51 angiographic outcomes 51 hindfoot 51 Neoadjuvant 51 TAXUS Element Paclitaxel Eluting 51 undergoing coronary artery 51 perioperative mortality 51 Metabolic Efficiency 51 stenoses 51 Navelbine 51 SORT OUT III 51 Phase III confirmatory 51 Endeavor stent 51 XIENCE TM 51 CLARITY TIMI 51 prespecified 51 Sibutramine Cardiovascular Outcomes 51 afatinib 51 ASCOT 51 posaconazole 51 radical nephrectomy 51 bendamustine 51 Acute Coronary Syndromes 51 microplasmin 51 liposome injection 51 salmeterol fluticasone 51 PARTNER Trial 51 ibandronate 51 postmenopausal women 51 REVIVE 51 renal artery stenting 51 MADIT 51 satraplatin Phase 51 intravesical 51 epidemiologic studies 51 carotid stent 51 zotarolimus eluting stent 51 ADAGIO study 51 intra arterial 51 revascularisation 51 NEO3 51 angiographic 51 Phase III trials 51 F FDG PET 51 maximally tolerated dose 51 relapsed APL 51 COPERNICUS 51 nephrectomy 51 SPARCL 51 enoxaparin 51 ENDEAVOR III 51 By JENNIFER LEARN 51 oxycodone CR 51 prucalopride 51 intravenous methylnaltrexone 51 cystectomy 51 ACCORD 51 histologically confirmed 51 drug eluting stent 51 TAXUS R 51 pharmacokinetic studies 51 nondiabetic patients 51 EOquin TM 51 peptic ulcer bleeding 51 MIVI TRUST 51 carotid revascularization 51 plain radiographs 51 platinum refractory 51 opioid induced bowel dysfunction 51 direct thrombin inhibitor 51 HYVET 51 GISSI HF 51 CYPHER 51 ID NCT# 51 vertebral fracture 51 dronedarone 51 Elocalcitol 51 Phase Ib IIa clinical 51 evaluable subjects 51 pharmacodynamic PD 51 radiographic outcomes 51 ximelagatran 51 desvenlafaxine succinate 51 antiepileptic drug 51 CardioFit 51 Evaluation WISE 51 photocoagulation 51 CLBP 51 CATIE AD 51 crizotinib PF # 51 XGEVA 51 ascending doses 51 coadministration 51 ARDIS 51 relapsed MM 51 periprocedural MI 51 superficial bladder cancer 51 MabCampath 51 PEGINTRON TM 51 CHAMPION PLATFORM 51 UKPDS 51 dose clopidogrel 51 fenretinide 51 paroxysmal AF 51 symptomatic paroxysmal AF 51 SCD HeFT 51 valsartan 51 bioabsorbable stent 51 Vascugel ® 51 Arimidex Tamoxifen Alone 51 Ranibizumab 51 PCI ExTRACT TIMI 51 V Everolimus Eluting Coronary 51 mRCC 51 pegylated liposomal doxorubicin 51 biliary tract cancer 51 mg/m2 dose 51 Dabigatran etexilate 51 macrovascular disease 51 nonmetastatic prostate cancer 51 clopidogrel 51 basal bolus regimen 51 bisphosphonate therapy 51 RezularTM 51 NSABP 51 bypass grafting 51 risperidone Risperdal 51 Cloretazine R VNP#M 51 Randomized Controlled 51 sorafenib Nexavar ® 51 biologic therapy 51 NAVISTAR R 51 PROPEL trial 51 QD dosing 51 HOPE TOO 51 LHRH receptor positive 51 Pivotal Phase 51 HuMax EGFr 50 lanthanum carbonate 50 MoxDuo TM IR 50 RAPAFLO R 50 Clinical Study 50 fully bioabsorbable 50 Taxotere R 50 atherosclerotic renal artery stenosis 50 trabedersen 50 relapsing multiple sclerosis 50 Tiotropium 50 Screening Trial 50 eltrombopag 50 IMPACT DCM clinical 50 PROTECT AF 50 AVANDIA 50 CTA# Injection 50 Observational Study 50 chemoradiation 50 AZILECT ® 50 RLAI 50 functional mitral regurgitation 50 ARIKACE 50 secondary endpoint 50 AVADO 50 occlusion CRVO 50 Neovascular AMD 50 PROMUS Element Everolimus Eluting 50 TM Drug Eluting 50 multicenter randomized Phase 50 gemcitabine 50 DES implantation 50 Pivotal Clinical Trial 50 Angiox R 50 oral anticoagulant 50 multidose 50 Nitinol Stent 50 Clolar ® 50 weekly subcutaneous injections 50 IIa clinical 50 BRAF inhibitor 50 C1 INH 50 KAPIDEX 50 Monitoring ABPM 50 neratinib 50 AZOR 50 vidofludimus 50 invasive bladder 50 antiarrhythmic drug 50 pneumonectomy 50 ALA PDT 50 number NCT# ClinicalTrials.gov 50 subconjunctival injection 50 pitavastatin 50 dyskinesia PD LID 50 pulmonary artery banding 50 oral anticoagulation 50 metastatic RCC 50 β blockers 50 Percutaneous 50 bevacizumab Avastin 50 GRAVITAS trial 50 cluster randomized controlled 50 ENVISION 50 pharmacokinetic 50 medically refractory 50 ZACTIMA 50 Xience V 50 HF ACTION 50 PROTECT II 50 atherogenic dyslipidemia 50 XIENCE V 50 neoadjuvant chemotherapy 50 glatiramer acetate 50 Ophena TM 50 FOLFIRI